AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?

Key Takeaways Lilly's Mounjaro and Zepbound drive half its revenues, fueling over 30% expected 2025 sales growth.AbbVie rebounds post-Humira LOE with Skyrizi and Rinvoq, targeting $25B in combined 2025 sales.2025 estimates for Lilly indicate 37% sales and 76.7% EPS growth, outpacing AbbVie's 7.6% and 18.9%.Eli Lilly (LLY) and AbbVie (ABBV) are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, robust R&D pipelines, strong market capitalization and global footprint. Bo ...